Ohashi, R.; Otake, S.; Murata, T.; Watari, R.; Yoshida, S.; Kitade, M.; Kondo, D.; Kimura, G.
Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate. Pharmaceutics 2025, 17, 1627.
https://doi.org/10.3390/pharmaceutics17121627
AMA Style
Ohashi R, Otake S, Murata T, Watari R, Yoshida S, Kitade M, Kondo D, Kimura G.
Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate. Pharmaceutics. 2025; 17(12):1627.
https://doi.org/10.3390/pharmaceutics17121627
Chicago/Turabian Style
Ohashi, Ryo, Shuichi Otake, Tatsuhiko Murata, Ryosuke Watari, Shinpei Yoshida, Mikiko Kitade, Daisuke Kondo, and Go Kimura.
2025. "Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate" Pharmaceutics 17, no. 12: 1627.
https://doi.org/10.3390/pharmaceutics17121627
APA Style
Ohashi, R., Otake, S., Murata, T., Watari, R., Yoshida, S., Kitade, M., Kondo, D., & Kimura, G.
(2025). Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate. Pharmaceutics, 17(12), 1627.
https://doi.org/10.3390/pharmaceutics17121627